Glipizide and Metformin Hydrochloride

FDA Drug Profile — Glipizide and Metformin Hydrochloride

Glipizide and Metformin Hydrochloride is listed in the FDA National Drug Code directory with 18 NDC codes, marketed under brand name including Glipizide and Metformin Hydrochloride. Available dosage form: tablet, film coated.

Drug details

Generic Name
Glipizide and Metformin Hydrochloride
Brand Names
Glipizide and Metformin Hydrochloride
Application Number
ANDA077270
Sponsor
REMEDYREPACK INC.
NDC Codes
18
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
METFORMIN HYDROCHLORIDE, GLIPIZIDE

Indications and Usage

INDICATIONS AND USAGE Glipizide and metformin hydrochloride tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Warnings

WARNINGS: LACTIC ACIDOSIS Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally > 5 mcg/mL [see PRECAUTIONS ] Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial disease. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see PRECAUTIONS ]. If metformin-associated lactic acidosis is suspected, immediately discontinue glipizide and metformin hydrochloride and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see PRECAUTIONS ].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.